Grifols SA (G0FB) Stock Price & Analysis
G0FB Stock Chart & Stats
- Day’s Range
- EUR 7.00 - EUR 7.00
- 52-Week Range
- EUR 5.95 - EUR 8.35
- Previous Close
- EUR 7.05
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 6.52B
- Enterprise Value
- EUR 16.75B
- Total Cash (Recent Filing)
- EUR 529.00M
- Total Debt (Recent Filing)
- EUR 8.52B
- Price to Earnings (P/E)
- 16.4
- Beta
- 0.54
- Next Earnings
- Nov 02, 2026 (Est.)
- EPS Estimate
- 0.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.37%
Bulls Say, Bears Say
Bulls Say
Immunoglobulin Growth
Strong immunoglobulin growth indicates sustained demand for Grifols’ core plasma-derived therapies, particularly subcutaneous products. Continued adoption can support revenue mix, manufacturing scale, and operating leverage over the next several quarters while reinforcing the company’s position in chronic-care treatment markets.
Improving Cash Generation
Improving profit and free cash flow strengthen Grifols’ ability to fund operations and strategic investment internally. Management also maintained full-year FCF guidance of €500–575 million, suggesting that better earnings quality and cash conversion may persist beyond a single reporting period.
Diversified Plasma Sourcing
Expanding ex-U.S. plasma collection, especially in Egypt, can improve supply self-sufficiency and plasma economics over time. The planned increase in collections provides a structural sourcing initiative that may support production capacity, reduce geographic concentration, and strengthen long-term Biopharma margins.
Bears Say
High Leverage
High leverage remains a durable constraint on financial flexibility despite some improvement from 2023 levels. Debt service and refinancing needs can absorb cash that might otherwise support growth or deleveraging, while elevated leverage leaves Grifols more exposed to operational setbacks and weaker earnings.
Weak Reported Revenue Trend
The sharp TTM revenue decline limits operating leverage and raises questions about the durability of demand and volume across the portfolio. Although H1 2026 returned to modest constant-currency growth, the broader reported trend indicates that improved margins are not yet supported by consistently expanding revenue.
Albumin Pressure In China
Pricing pressure in China weighs on albumin performance and demonstrates that an important product market remains exposed to reimbursement and pricing dynamics. Management expects stabilization in H2, but the headwind has already affected H1 results and can constrain mix, revenue quality, and margins near term.
Grifols SA News
G0FB FAQ
What was Grifols SA’s price range in the past 12 months?
What is Grifols SA’s market cap?
When is Grifols SA’s upcoming earnings report date?
How were Grifols SA’s earnings last quarter?
Is Grifols SA overvalued?
Does Grifols SA pay dividends?
What is Grifols SA’s EPS estimate?
How many shares outstanding does Grifols SA have?
What happened to Grifols SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Grifols SA?
What is the TipRanks Smart Score and how is it calculated?
Grifols SA Stock Smart Score
Company Description
Grifols SA
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Jose Ignacio Abia Buenache
- Employees
- 25,258
- Website
- www.grifols.com
- Address
- Parque Empresarial Can Sant Joan, Barcelona, CT, 08174, ES
Grifols SA (G0FB) Earnings & Revenues
G0FB Company Deck
G0FB Earnings Call
Earnings Call SentimentPositive
Overall the call conveys a constructive and confident tone: the company reported modest top-line growth with strong momentum in Biopharma—notably IG and subcutaneous IG—improving adjusted EBITDA, higher group profit, and better free cash flow. Strategic initiatives (Egypt plasma ramp, diagnostics platform development, Biopharma reorganization, Biotest turnaround) and debt refinancing strengthen the long‑term profile. Near-term headwinds include albumin pricing effects in China, one‑off costs from donor center closures, and transitional diagnostics comparability, but management provided clear mitigation plans and timing for expected benefits.
View all DE:G0FB earnings summariesG0FB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 11 | 0 | 1 |
